bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.04.29.651177

The absence of the ompA and type VI secretion system in the successful lineage of Acinetobacter baumannii ST19

Abstract

Acinetobacter baumannii is an opportunistic pathogen, often multi- to pandrug-resistant, including to last-resort antibiotics such as carbapenems. A. baumannii can acquire DNA through multiple mechanisms including natural competence and conjugation. An active Type VI Secretion System (T6SS), which kills nonkin bacteria and challenges and inhibits the conjugation. The acquisition of resistance genes has helped the spread of resistant clones of A. baumannii, such as those of Sequence Types (STPas), ST1, ST2, ST10, ST15, ST25, ST79 and ST85. While ST1 and ST2 were thoroughly studied, there are new emerging clones whose genetic background facilitating the rise is still unknown or poorly understood. The emergence of Acinetobacter baumannii ST19 first peaked in 2003, coinciding with the Iraq conflict and increased detection among U.S. military personnel. Its prevalence later surged in Georgia and Ukraine, around the onset of the conflict in Ukraine in 2022, associating it with regions affected by military activity. In this study, we have sequenced whole-genome three isolates of A. baumannii ST19 and compared them with further 156 A. baumannii ST19 genomes were obtained from public repositories. In total, 157/159 genomes revealed loss of T6SS locus, which was replaced in 56/157 genomes (35,7%) by {Delta}Tn9 carrying chloramphenicol and {Delta}Tn10 carrying tetracycline resistance genes, and formaldehyde and chlorite resistance genes. Surprisingly, the antibiotic resistance-encoding transposons likely originated from Enterobacteriaceae plasmids. The loss of a functional T6SS in A. baumannii ST19 may potentially facilitate horizontal gene transfer and promoting a cooperative or less competitive lifestyle providing a selective advantage at the population level.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Valcek, A., Strachinaru, I., Nesporova, K., Soentjens, P., Stoefs, A., Van der Henst, C.. 2025-04-29. The absence of the ompA and type VI secretion system in the successful lineage of Acinetobacter baumannii ST19. https://doi.org/10.1101/2025.04.29.651177

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗